BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Edinger JT, Clark BZ, Pucevich BE, Geskin LJ, Swerdlow SH. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol. 2009;33:1860-1868. [PMID: 19898220 DOI: 10.1097/pas.0b013e3181bf677d] [Cited by in Crossref: 68] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Kadin ME, Pavlov IY, Delgado JC, Vonderheid EC. High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides. J Invest Dermatol. 2012;132:703-710. [PMID: 22071475 DOI: 10.1038/jid.2011] [Reference Citation Analysis]
2 Danish HH, Heumann TR, Bradley KT, Switchenko J, Esiashvili N, Lechowicz MJ, Flowers CR, Khan MK. CD30+ Cutaneous T Cell Lymphoma: Response to Rotational Total Skin Electron Irradiation. Dermatol Ther (Heidelb) 2016;6:251-63. [PMID: 27085537 DOI: 10.1007/s13555-016-0115-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
3 Vieyra-Garcia P, Fink-Puches R, Porkert S, Lang R, Pöchlauer S, Ratzinger G, Tanew A, Selhofer S, Paul-Gunther S, Hofer A, Gruber-Wackernagel A, Legat F, Patra V, Quehenberger F, Cerroni L, Clark R, Wolf P. Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial. JAMA Dermatol 2019;155:538-47. [PMID: 30892603 DOI: 10.1001/jamadermatol.2018.5905] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 21.0] [Reference Citation Analysis]
4 van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J 2017;7:e603. [PMID: 28885612 DOI: 10.1038/bcj.2017.85] [Cited by in Crossref: 70] [Cited by in F6Publishing: 57] [Article Influence: 17.5] [Reference Citation Analysis]
5 Chen X, Soma LA, Fromm JR. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. Onco Targets Ther 2013;7:45-56. [PMID: 24379682 DOI: 10.2147/OTT.S39107] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
6 Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 2015;33:3766-73. [PMID: 26438120 DOI: 10.1200/JCO.2015.61.7142] [Cited by in Crossref: 196] [Cited by in F6Publishing: 54] [Article Influence: 32.7] [Reference Citation Analysis]
7 Nashan D, Friedrich CM, Geissler E, Schmitt-Graeff A, Klein F, Meiss F. [Primary cutaneous lymphoma-a case series of 163 patients]. Hautarzt 2018;69:1014-20. [PMID: 29881891 DOI: 10.1007/s00105-018-4212-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Kadin ME, Pavlov IY, Delgado JC, Vonderheid EC. High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides. J Invest Dermatol 2012;132:703-10. [PMID: 22071475 DOI: 10.1038/jid.2011.351] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
9 Virmani P, Myskowski PL, Pulitzer M. Unusual variants of mycosis fungoides. Diagn Histopathol (Oxf) 2016;22:142-51. [PMID: 29225700 DOI: 10.1016/j.mpdhp.2016.04.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
10 Pulitzer M, Myskowski PL, Horwitz SM, Querfeld C, Connolly B, Li J, Murali R. Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors. Pathology 2014;46:610-6. [PMID: 25393251 DOI: 10.1097/PAT.0000000000000166] [Cited by in Crossref: 29] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
11 Ma H, Abdul-Hay M. T-cell lymphomas, a challenging disease: types, treatments, and future. Int J Clin Oncol 2017;22:18-51. [PMID: 27743148 DOI: 10.1007/s10147-016-1045-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
12 Vaklavas C, Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol 2012;3:209-25. [PMID: 23606932 DOI: 10.1177/2040620712443076] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 6.6] [Reference Citation Analysis]
13 Yi JH, Kim SJ, Kim WS. Brentuximab vedotin: clinical updates and practical guidance. Blood Res 2017;52:243-53. [PMID: 29333400 DOI: 10.5045/br.2017.52.4.243] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
14 Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, Rozati S, Nagpal S, Krathen M, Reddy S, Hoppe RT, Nguyen-Lin A, Weng WK, Armstrong R, Pulitzer M, Advani RH, Horwitz SM. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol 2015;33:3750-8. [PMID: 26195720 DOI: 10.1200/JCO.2014.60.3969] [Cited by in Crossref: 161] [Cited by in F6Publishing: 46] [Article Influence: 26.8] [Reference Citation Analysis]
15 Pulitzer M. Cutaneous T-cell Lymphoma. Clin Lab Med 2017;37:527-46. [PMID: 28802499 DOI: 10.1016/j.cll.2017.06.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]